Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash | 9 | 8 | 6 | 6 | 5 | 4 | 6 | 6 | 9 | 7 | 7 | 9 | |||||
Accounts And Other Receivables Net Current | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | - | - | |||||
Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Current | - | - | - | 6 | 5 | - | 6 | - | - | - | 7 | 9 | |||||
Assets | 10 | 8 | 6 | - | - | 4 | - | 7 | 9 | 8 | - | - | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable And Accrued Liabilities Current | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Liabilities Current | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Liabilities | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Stockholders Equity | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 84 | 81 | 77 | 75 | 72 | 68 | 67 | 65 | 64 | 58 | 52 | 51 | |||||
Retained Earnings Accumulated Deficit | -77 | -75 | -74 | -72 | -69 | -67 | -65 | -62 | -58 | -53 | -48 | -45 | |||||
Stockholders Equity | 7 | 5 | 4 | 4 | 2 | 1 | 3 | 3 | 6 | 5 | 4 | 6 | |||||
Liabilities And Stockholders Equity | 10 | 8 | 6 | 6 | 5 | 4 | 6 | 7 | 9 | 8 | 7 | 9 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | - | - | - | 0.001 | - | - | - | - | - | - | |||||
Preferred Stock Shares Authorized | 10 | 10 | - | - | - | 10 | - | - | - | - | - | - | |||||
Preferred Stock Shares Issued | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Preferred Stock Shares Outstanding | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 250 | 250 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | |||||
Common Stock Shares Issued | 3 | 2 | 2 | 1 | 22 | 1 | 17 | 16 | 16 | 14 | 13 | 13 | |||||
Shares Outstanding | 3 | 2 | 2 | 1 | 22 | 1 | 17 | 16 | 16 | 14 | 13 | 13 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -22.94% | -26.61% | - | - | - | - | - | - | - | - | - | - |
| 2025 | -12.15% | 22.03% | -22.28% | -8.93% | 1.56% | 12.05% | -35.54% | -44.58% | -52.51% | -26.55% | -56.89% | -60.48% |
| 2024 | 14.83% | -1.44% | 0.96% | 15.79% | 1.05% | -3.16% | -59.46% | -51.89% | -60.49% | -25.16% | -23.89% | -26.64% |
| 2023 | -3.63% | -12.54% | -36.63% | 1.48% | -17.72% | 195.12% | 14.29% | 11.43% | -8.86% | -29.04% | -20.22% | -7.72% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Acurx Pharmaceuticals, Inc. (ACXP) — SEC Financial Statements & Analysis
Acurx Pharmaceuticals, Inc. (ACXP) is a pharmaceutical preparations company, incorporated in DE. Acurx Pharmaceuticals, Inc. trades on Nasdaq as: ACXP. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Acurx Pharmaceuticals, Inc. reported a Debt-to-Equity ratio of 0.36x, a Price-to-Book (P/B) ratio of 1.44 (TTM), at a market cap of $10.09M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.36x
- P/B TTM
- 1.44
- Market Cap
- $10.09M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Acurx Pharmaceuticals, Inc. in?
Acurx Pharmaceuticals, Inc. (ACXP) operates in the Pharmaceutical Preparations industry.
What is ACXP's market cap?
Acurx Pharmaceuticals, Inc. (ACXP) has a market capitalization of $10.09M as of 2026-03-31.
What exchange does ACXP trade on?
Acurx Pharmaceuticals, Inc. (ACXP) trades on the Nasdaq.
Where is Acurx Pharmaceuticals, Inc. incorporated?
Acurx Pharmaceuticals, Inc. is incorporated in DE.